Attendee search 

Viscadia is an analytically-driven management consulting firm that partners with companies in specialty pharmaceutical markets. Viscadia identifies and evaluates development, acquisition, licensing and life-cycle management opportunities. Additionally, Viscadia analyzes and optimizes the execution of specialty pharmaceutical commercial strategies. Viscadia is headquartered in San Diego, CA with a regional office in St. Louis, MO. For more information about Viscadia, email info@viscadia.com, call +1 858 496 7500 or visit www.viscadia.com.

ImmunGene is leveraging promising science to empower therapeutic antibodies with immune molecules.  These molecules are highly optimized for dramatic efficacy and a superior safety profile. 

Our technology allows us to genetically engineer cytotoxic cytokines to antibodies to selectively target disease causing cells and tissues while reducing the systemic toxicity of the cytokines.  ImmunGene has several antibody molecules genetically engineered with interferon for following indications:

Non-Hodgkins lymphoma

Leukemia

Multiple myeloma

Melanoma

Renal cancer

Prostate cancer

Breast Cancer

AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Our lead product, ARX-01, is currently being evaluated in Phase 3 studies for the treatment of moderate to severe acute pain in the hospital setting. ARX-01 is designed to enable patient control, remove impediments to ambulation, and improve patient satisfaction. By utilizing sublingual delivery of sufentanil NanoTabs(R) thorugh our proprietary handheld system, ARX-01 avoids the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. By delivering sufentanil through the oral transmucosal route, ARX-01 offers the potential to improve upon the typical side effect profile of morphine. 

We have three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.

GLG Research partners with organizations seeking efficient, targeted connections to insight.

Our Healthcare Practice provides you with access to expert insights on issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors. GLG works with:

• 9 of the top 10 pharmaceutical and biotechnology companies
• More than 80,000 experts from across the entire healthcare industry including physicians, researchers, scientists, payors, and healthcare industry executives
• 7 out of the top 10 global medical equipment companies
• Over 300,000 experts from all sectors, including former C-level operating executives, ex-top-tier strategy consultants and thought leaders from around the world

Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. The firm’s clients include all of the world’s top-20 pharmaceuti­cal companies, hundreds of emerging and midsize biopharmaceutical companies, as well as a number of medical device and diagnostics companies. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Clinical Development, Commercial Effectiveness, Corporate Development, Medical Affairs, and Pricing and Market Access. From its locations in Cambridge, MA; Conshohocken, PA; Deerfield, IL; London, UK; Newtown, PA; New York, NY; Parsippany, NJ; Raleigh, NC; Somerset, NJ; South San Francisco, CA; Thousand Oaks, CA; and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan.

Acorda Therapeutics, Inc. is a biotechnology company whose mission is to develop and market therapies that restore neurological function and improve the lives of people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The Company's marketed products include AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. and ZANAFLEX CAPSULES® (tizanidine hydrochloride). AMPYRA® is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. ZANAFLEX CAPSULES® is a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.